← Imunon, Inc. (IMNN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Imunon, Inc. (IMNN)
Pharmaceutical Preparations · market cap $8M · as of 2026-10-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Imunon (IMNN) is a micro-cap clinical-stage biotech with a market cap of about $6M (~5.6M shares at ~$1.08). Its lead asset, IMNN-001, is an IL-12 plasmid formulated with a PEG-PEI-Cholesterol lipopolymer, listed in our data at Phase 3 for epithelial ovarian cancer. The setup is dominated by a cash position of $6.9M against 6.8 months of runway, so financing is the central near-term variable.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-06-30 (est.)Phase 2 · IMNN-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMNN-101 | Phase 2 | SARS CoV 2 Infection |
| IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | Phase 3 | Epithelial Ovarian Cancer |
| ThermoDox | Phase 3 | Hepatocellular Carcinoma |
| ThermoDox in combination with Microwave Hyperthermia (heat) | Phase 2 | Breast Cancer |
| IMNN-001 | Phase 2 | Epithelial Ovarian Cancer |
| Dextrose | Phase 3 | Hepatocellular Carcinoma |
Price & technical context
3-month
-44.1%
6-month
-67.0%
12-month
-76.7%
52-wk range
$0.83–$4.22
vs 50-day MA
-28.3%
vs 200-day MA
-58.8%
Realized vol
65.0%
Max drawdown
-97.5%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMNN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.